BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Biohaven Pharmaceutical Holding Company Ltd.

BHVN

VGG111961055

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:40:00 2024-05-16 am EDT			5-day change	1st Jan Change
36.92 ^USD	-0.42%		-9.07%	-75.63%

May. 15	Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	MT
May. 14	Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	MT

Biohaven Pharmaceutical Holding Company Ltd. Re-Affirms Sales Guidance for the Full Year 2022

August 05, 2022 at 07:00 am EDT

Biohaven Pharmaceutical Holding Company Ltd. re-affirmed sales guidance for the full year 2022. For the year, the company expected net product sales of $825 million to $900 million.

Latest news about Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	May. 15	MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	May. 14	MT
Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	May. 10	MT
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	Apr. 25	MT
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	Apr. 23	MT
UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating	Apr. 23	MT
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	Apr. 23	MT
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	Apr. 23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Biohaven Prices $230 Million Public Share Offering	Apr. 18	MT
Biohaven Launches $200 Million Common Stock Offering	Apr. 17	MT
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	Mar. 04	MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	Mar. 01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	Mar. 01	MT
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	Feb. 29	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	Feb. 16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	Feb. 06	MT
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	Jan. 02	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	Dec. 08	MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	Nov. 20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	Nov. 15	MT
Biohaven Pharmaceutical Q3 Net Loss Narrows	Nov. 14	MT
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass	23-10-16	MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing	23-10-11	MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing	23-10-10	MT

Chart Biohaven Pharmaceutical Holding Company Ltd.

Duration

Period

Chart Biohaven Pharmaceutical Holding Company Ltd.

More charts

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.	-75.63%	541M
MODERNA, INC.	+31.14%	49.46B
IQVIA HOLDINGS INC.	+1.13%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+12.67%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-23.78%	18.64B
BIO-TECHNE CORPORATION	+7.40%	13.16B
MEDPACE HOLDINGS, INC.	+31.63%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.06%	12.1B

Other Biotechnology & Medical Research